Sareum and ReceptorAI collaborate on TYK2/JAK1 inhibitors
Sareum Holdings and Receptor.AI have entered into a strategic collaboration focused on accelerating the discovery and optimisation of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors. The goal of the agreement is to generate high-quality candidates suitable for preclinical development in neuroinflammatory indications, such as multiple sclerosis and Parkinson’s… Read More